A 24-Week, Phase IIa, Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)

By sjmartinez • February 15, 2023

Khanna D, Denton CP, Furst DE, Mayes MD, Matucci-Cerinic M, Smith V, de Vries D, Ford P, Bauer Y, Randall MJ, Ebrahimpoor M, Kupcsik L, Stiers PJ, Deberdt L, Prasad N, Lim S, Pujuguet P, Ahmed S. A 24-Week, Phase IIa, Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA). Arthritis Rheumatol. 2023 Feb 14. doi: 10.1002/art.42477. Epub ahead of print. PMID: 36787101.

Tags: Publications, Rheumatology

The Effect of Urban Heat Island Intensity on the Rate of Emergency Department Visits for Acute Myocardial Infarctions

Lilley B, Amubieya O, Ziaeian B. The Effect of Urban Heat Island Intensity on the Rate of Emergency Department Visits for Acute Myocardial Infarctions. Eur[...]

Impact of e-cigarettes and flavoured vapes on respiratory health: where are we now?

Omcikus M, Tashkin DP, Dimic-Janjic S, Barjaktarevic I. Impact of e-cigarettes and flavoured vapes on respiratory health: where are we now? Curr Opin Pulm Med.[...]

KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy

Rugo HS, Cescon DW, Robson ME, Im SA, Dalenc F, Yañez Ruiz E, Reyes-Cosmelli F, Walshe JM, Im YH, Kulyk S, Dudnichenko O, Llinás-Quintero N,[...]